|
|
|
| Mechanism and Application of New Immunosuppressant |
| HAO Hui-yun, WANG Yao-yao, ZHU Yan-yan, FU Mei-hong, WANG Ya-li |
| NCPC New Drug Research and Development Corporation, Ltd., National Engineering Research Center of Microbial Medicine, Hebei Industrial Microbiology Metabolic Engineering and Technology Research Center, Shijiazhuang 050015,China |
|
|
|
|
Abstract Immunosuppressive drugs have been widely used in organ transplantation and treatment of autoimmune disease. At present, many adverse reactions exist in clinical use of these agents. In order to obtain better treatment effect, researchers have exploited some novel immunosuppressants which are high efficient and low toxicity. The mechanisms, clinical applications and adverse reactions of FTY720, FK-778, everolimus and efalizumab were summarized. It was pointed out that the development of new type, efficient, low toxicity and low price immunosuppressants and the formation of new treatments are still one of the important research topics for immunopharmacology workers.
|
|
|
|
|
|
| [ 1 ] 高明明，高向东，顾觉奋. 新型免疫抑制剂FTY720的研究进展[J].国外医药抗生素分册，2007， 28（5 ）：215 - 224.[ 2 ] Klemens B，Robert L，Schmouder A，et al.Frist human trial of FTY720，a novel immunomodulater， in stable renal transplant patients [J].J Am Soc Nephrol，2002，13（4 ）：1 073 - 1 083. [ 3 ] 杨之斌.FTY720免疫抑制和抗肿瘤双重作用的研究进展[J]. 免疫学杂志，2004，20（ 3 ）：8 - 11. 4 ] 潘 祺，李作孝. FTY720在多发性硬化治疗作用中的研究进展[J].西南军医，2012，14（1 ）：95 - 96.[ 4 ] 肖江卫，王崇树，等.FTY720抑制裸鼠人肝癌细胞系MHCC - 97H移植瘤生长的实验研究[J]. 实用癌症杂志， 2010， 25（ 2 ）：122 - 125.[ 5 ] 刘 莹，王玉斌，等.新型小分子免疫抑制剂研究进展[J]. 中国新药杂志，2011，20 （20 ）：1 981 - 1 988. |
|
|
|
